Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Albendazole Tablets USP, 200 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Albenza® Tablets, 200 mg, of Impax Laboratories Inc.
Albendazole Tablets USP, 200 mg, are an anthelmintic drug indicated for treatment of:
- Parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm
- Cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm
Albendazole Tablets USP (RLD: Albenza®) had an annual sales of approximately USD 34 million in the U.S. (IQVIA MAT April 2020).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.
Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on
For further information or queries please contact –
Head – Investor Relations/Corporate M&A
General Manager – Corporate Communications
Albenza® is a registered trademark of GlaxoSmithKline LLC Limited.